UNSPSC 51263171: Penbutolol sulfate

This classification denotes a beta-adrenergic blocking agent and antiarrhythmic agent with the molecular formula 2C18H29NO2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier US71433228, chemically known as 2-propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-, (s)-, sulfate (2:1) (salt) but more generally known as penbutolol sulfate, which bears US NIH Compound Identifier 38010.

UNSPSC 51263171 Penbutolol sulfate is a Commodity code that nominally covers a specific beta-blocker pharmaceutical product, but recent state and local procurement activity under this code shows minimal alignment with the code's explicit scope. The most recent opportunities posted under this code involve naloxone procurement and direct-to-manufacturer prescription program capabilities — neither of which involves penbutolol sulfate — suggesting that state and local purchasing offices may be using this code as a catch-all placeholder for pharmaceutical acquisitions or health-related drug procurement rather than for the specific active pharmaceutical ingredient named in the code.

Issuing bodies using this code include county health departments and state health agencies. Seminole County, Florida posted an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore vendor capabilities for a direct-to-manufacturer prescription program serving self-insured employee group health plans and state agencies outside traditional pharmacy benefit manager arrangements. Geographic activity is limited to Florida and Texas based on recent postings. Bid and RFI responses require E-Verify compliance, drug-free workplace certification, and standard insurance coverage in the Seminole County opportunity; the Texas RFI is a preliminary market-intelligence mechanism with no formal award timeline or budget identified. The code's recent activity does not support reliable characterization of penbutolol sulfate procurement specifically — bidders should clarify with issuing bodies whether this code designation reflects actual pharmaceutical specification or administrative classification before investing in pursuit.